Concepedia

Matko Kalac

MK

11

Publications

612

Citations

10

H-Index

2007

Active since

Affiliations

Columbia University Irving Medical Center(Current)

National Center for Tumor Diseases

Peter MacCallum Cancer Centre

University Hospital Heidelberg

Heidelberg University

Matko Kalac is an author at Columbia University Irving Medical Center specializing in pathology, medicine, and cancer therapeutics.

Top concepts

Publications per year

2007–2025

11

Publications

11

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

Matko Kalac, Luigi Scotto, Enrica Marchi et al. · Blood · 2011 · 151 citations · Full text

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Jennifer E. Amengual, Renee Lichtenstein, Jennifer Kimberly Lue et al. · Blood · 2017 · 128 citations · Full text

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial

Owen A. O’Connor, Jennifer Kimberly Lue, Ahmed Sawas et al. · The Lancet Oncology · 2017 · 113 citations · Full text

, , +5

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

Jennifer E. Amengual, Sean Clark-Garvey, Matko Kalac et al. · Blood · 2013 · 60 citations

The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T‐cell lymphoma

Enrica Marchi, Kelly Zullo, Jennifer E. Amengual et al. · British Journal of Haematology · 2015 · 59 citations

Rows per page

1–5 of 11